{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-421761","form_type":"8-K","ticker":"ELVN","cik":"0001672619","company_name":"Enliven Therapeutics, Inc.","filed_at":"2026-10-14T20:39:15+00:00","discovered_at":"2026-10-14T20:40:00.261930+00:00","generated_at":"2026-10-14T20:40:04.363887+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Enliven Therapeutics adds Kristine Ball to board; Phase 3 relcobatinib trial to start before year-end","bullets":["Board expanded from seven to eight directors; Ball appointed Class II director effective Oct. 14, 2026, term expiring at the 2028 annual meeting, and joins the Audit Committee.","Compensation: $45,000/year as outside director plus $10,000/year for Audit Committee service, and stock options with grant-date fair value of about $650,000.","Options vest 1/36th monthly, with full acceleration on a Change in Control; Ball also signed the company's standard indemnification agreement.","Ball was CEO of Antiva Biosciences and Soteria Biotherapeutics and CFO of Menlo Therapeutics and Relypsa; she chairs Oruka Therapeutics' audit committee.","Company reaffirmed plans to initiate the pivotal Phase 3 trial of relcobatinib (ELVN-001) in previously treated CML before year-end 2026 after FDA alignment on ENABLE-2 design."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-421761","json":"https://secwatch.observer/filing/0001193125-26-421761.json","markdown":"https://secwatch.observer/filing/0001193125-26-421761.md","text":"https://secwatch.observer/filing/0001193125-26-421761.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672619/000119312526421761/0001193125-26-421761-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672619/000119312526421761/d13112d8k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-14T20:40:04.363887+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}